Oslo  (Norway),  6 April  2021 -  PCI  Biotech  (OSE:  PCIB),  a  clinical-stage
biopharma  company developing  innovative therapeutics  that address significant
unmet  medical  needs  in  cancer  today  announced  that it will present at the
European  Biotech Investor Days 2021, a US based online event taking place April
7-8, 2021 and hosted by Goodwin, Solebury Trout, Deutsche Bank and Nasdaq.

On Thursday, April 8, 2021 at 15:00 (CEST), Dr. Per Walday, CEO, will present an
overview  of PCI Biotech's proprietary platform technology via a general company
presentation.

The     presentation    can    be    accessed    live    through    this    link
https://showroom.troutaccess.com/app?iframe=1#/webcast/GHAQ5D

The  presentation  slides  will  be  made  available  on  PCI  Biotech's website
(www.pcibiotech.com) under "Other presentations" after the event.

Contact information:
Per Walday, CEO
pw@pcibiotech.no
Mobile: +47 917 93 429

About PCI Biotech
PCI  Biotech  is  a  biopharmaceutical  late  stage clinical development company
focusing  on  development  and  commercialisation  of  novel  therapies  for the
treatment  of cancer through its  innovative photochemical internalisation (PCI)
technology  platform.  PCI  is applied  to three  distinct anticancer paradigms:
fimaChem  (enhancement of chemotherapeutics for  localised treatment of cancer),
fimaVacc  (T-cell induction technology for therapeutic vaccination), and fimaNAc
(nucleic acid therapeutics delivery).

Photochemical  internalisation induces triggered endosomal  release that is used
to  unlock the  true potential  of a  wide array  of therapeutic modalities. The
company's  lead  programme  fimaChem  consists  of  a pivotal study in bile duct
cancer,  an  orphan  indication  with  a  high  unmet  need and without approved
products.  fimaVacc applies  a unique  mode of  action to  enhance the essential
cytotoxic  effect of  therapeutic cancer  vaccines, which  works in synergy with
several  other state-of-the-art  vaccination technologies.  fimaNAc utilises the
endosomal  release to provide  intracellular delivery of  nucleic acids, such as
mRNA  and RNAi  therapeutics, thereby  addressing one  of the  major bottlenecks
facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com

Forward-looking statements

This  announcement may contain forward-looking statements, which as such are not
historical  facts, but  are based  upon various  assumptions, many  of which are
based,  in  turn,  upon  further  assumptions.  These assumptions are inherently
subject  to  significant  known  and  unknown  risks,  uncertainties  and  other
important  factors. Such risks, uncertainties, contingencies and other important
factors  could cause  actual events  to differ  materially from the expectations
expressed  or implied in  this announcement by  such forward-looking statements.
PCI  Biotech disclaims  any obligation  to update  or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

This  information is subject to the  disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.